Abstract 97P
Background
Myocarditis is a rare adverse effect of immune-checkpoint inhibitor therapy (ICI) associated with a high fatality rate and no clear predeterminants. European Society of Cardiology suggests baseline cardiac assessment and serial monitoring with ICI treatment. The volume of investigations recommended has been a barrier to adoption in practice.
Methods
We conducted a prospective study of clinical utility of baseline and serial cardiac assessment in a UK tertiary hospital. Patients were risk stratified by cardiac history, risk factors, baseline bloods including cardiac biomarkers and cardiac investigations, repeated at 3-4 weeks and 6-8 weeks. Aims; test feasibility; assess the value in risk stratifying patients to predict risk; determine if serial monitoring identified early cardiac toxicity.
Results
175 patients, 86 High risk, 89 Low risk. 8/175 patients baseline troponin >30. 28/175 patients baseline BNP >400. 2 patients had a troponin rise at 3-4 week, neither developed cardiotoxicity. 7 developed a troponin rise at 6-8 weeks, none developed cardiotoxicity. 32 patients had a BNP rise at 3-4 weeks. 9 significant. 1 patient BNP increased to >1000 without cardiotoxicity. 5 patients BNP approximately doubled; 2 patients rose >1000, 1 without cardiotoxicity, 1 who developed myocarditis later. 2 symptomatic patients with raised biomarkers and were treated for cardiotoxicity. 1 presented in SVT, LVEF 33%, CMR negative for myocarditis. 1 with syncopal episodes. In both cases biomarkers reduced on steroids, ICI was terminated.
Conclusions
All patients who developed cardiotoxicity were screened as high risk. 2 patients with cardiotoxicity were identified through clinical assessment not serial monitoring. Interpretation of cardiac biomarkers should accompany careful clinical assessment and liaison with cardiology. Baseline assessment supports decision making. Risk stratification may be a way to streamline monitoring.
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
21P - Impact of TP53 mutation subtypes on the efficacy of anti-PD-(L)1 immunotherapy in patients with non-small cell lung cancer
Presenter: Lige Wu
Session: Poster Display session
Resources:
Abstract
22P - Extracellular vesicles as predictive biomarkers for chemoimmunotherapy in biliary tract cancer
Presenter: Michele Zanoni
Session: Poster Display session
Resources:
Abstract
23P - Non-small cell lung cancer DNA methylation profiles correlate with immune checkpoint inhibitor response
Presenter: Julia Berger
Session: Poster Display session
Resources:
Abstract
24P - Blood DNA methylation profiles in NSCLC patients treated with immune checkpoint inhibitors
Presenter: Markus Kleinberger
Session: Poster Display session
Resources:
Abstract
25P - Circulating tumor DNA is predictive of overall survival in patients with metastatic uveal melanoma
Presenter: Egle Ramelyte
Session: Poster Display session
Resources:
Abstract
26P - Liquid biopsy-based percision immunotherapy: CCAT1 and HEIH lncRNAs identify young breast cancer patients likely to respond to PD-L1 blockade
Presenter: Rana Youness
Session: Poster Display session
Resources:
Abstract
27P - Single cell RNA sequencing (scRNAseq) analysis of peripheral immune cell populations from patients treated with anti-PD1 with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
Presenter: Séverine Carlier
Session: Poster Display session
Resources:
Abstract
28P - Circulating biomarkers in non-small cell lung cancer patients treated with immune checkpoint inhibitors
Presenter: Paola Ulivi
Session: Poster Display session
Resources:
Abstract
29P - Prognostic value of systemic inflammatory index and platelet-to-lymphocyte ratio in muscle-invasive bladder cancer patients treated with neoadjuvant chemo-immunotherapy in the AURA trial
Presenter: Jeremy Blanc
Session: Poster Display session
Resources:
Abstract
30P - The prognostic value of low density neutrophils in breast cancer: Implications for therapeutic strategies
Presenter: Telma Martins
Session: Poster Display session
Resources:
Abstract